13 results
Summary of dosing recommendations in renal impairment of commonly used hypoglycaemic agents

#Diabetes #Diabetic #Medications #Pharmacology #Dosing
Summary of dosing ... hypoglycaemic agents #Diabetes ... #Diabetic #Medications ... #Pharmacology # ... Renal #Impairment #CKD
Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or
Patients With Type 2 Diabetes ... 3A, 3B, or 4 Diabetes ... #Metformin #CKD3 ... #CKD4 #Dosing # ... Pharmacology #VisualAbstract
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... GLP-1 receptor agonists ... Improved outcomes in CKD ... EricsMedicalLectures/featured #diabetes
Sulfonylureas - Pharmacology Summary
Mechanisms of Action: Binds to the ATP-sensitive potassium channel in pancreatic beta cells,
Sulfonylureas - Pharmacology ... Summary Mechanisms ... contraindicated in CKD ... #Summary #DM2 # ... diabetes #endocrinology
Algorithm for Metformin Prescribing and Dosing in CKD
Dose Initiation - Immediate release:
 • Initial 500 mg
Prescribing and Dosing ... in CKD Dose Initiation ... #Prescribing #Dosing ... #CKD #pharmacology ... #algorithm #diabetes
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
GLP-1 Receptor Agonists ... - Pharmacology ... Summary Mechanisms ... #Pharmacology # ... Summary #DM2 #diabetes
Estimating the Total Daily Dose (TDD) of Insulin: Weight-Based Dosing
TDD in units of insulin = N
: Weight-Based Dosing ... (stage IV or V CKD ... #TDD #Insulin #dosing ... Weight #Based #pharmacology ... endocrinology #diabetes
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
GLP-1 Agonists ... Daily GLP-1 Agonists ... to treat Type 2 Diabetes ... #Pharmacology #Dosing ... #Diabetes #DM2
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
4 Inhibitors - Pharmacology ... Summary Mechanisms ... GLP-I receptor agonist ... #Summary #DM2 # ... diabetes #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
First Oral GLP-1 Agonist ... Dosing: 3 mg ... oral route by using ... #semaglutide #Diabetes ... #Pharmacology #